HIV-induced T-cell syncytia release a two component T-helper cell chemoattractant composed of Nef and Tat.
Using a newly developed gradient chamber to provide independent measurements of chemokinesis (stimulated motility) and chemotaxis (stimulated motility up a concentration gradient) of individual T-helper cells, it was recently demonstrated that HIV-induced T-cell syncytia release two distinct chemotactic activities that are separable by their rates of diffusion. The molecular masses of the two chemoattractant activities were estimated to be 30 and 120 kDa. The higher molecular mass activity was demonstrated to be the viral glycoprotein gp120. In an attempt to identify the lower molecular mass activity, chemotaxis and chemokinesis of T-helper cells were analyzed in individual concentration gradients of the virally encoded proteins Rev, p24, Tat and Nef. None functioned alone as a chemoattractant, but both Tat and Nef alone functioned as chemokinetic stimulants. When Tat and Nef were used together to generate parallel gradients, they stimulated chemotaxis. Antibody to either Tat or Nef neutralized the lower molecular mass chemotactic activity released by syncytia. The addition of antibody to the CD4 receptor or the addition of soluble CD4 inhibited high molecular mass chemotactic activity but not the low molecular mass chemotactic activity in HIV-induced syncytium-conditioned medium, demonstrating that the former but not the latter activity is mediated through the CD4 receptor. These results identify the combination of Nef and Tat as the lower molecular mass T cell chemoattractant released by HIV-induced syncytia, and provide the first evidence suggesting that parallel concentration gradients of two proteins are necessary for chemotaxis.
Shutt
D C
DC
Department of Biological Sciences, University of Iowa, Iowa City, Iowa 52242, USA.
Soll
D R
DR
D015704:CD4 Antigens / Q000502:physiology; D002478:Cells, Cultured; D002630:Chemotactic Factors / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D002633:Chemotaxis / Q000187:drug effects; D017077:Culture Media, Conditioned / Q000737:chemistry; D004357:Drug Synergism; D015693:Gene Products, nef / Q000378:metabolism* / Q000494:pharmacology; D015696:Gene Products, tat / Q000378:metabolism* / Q000494:pharmacology; D015726:Giant Cells / Q000378:metabolism / Q000821:virology*; D015497:HIV-1; D006801:Humans; D013601:T-Lymphocytes / Q000166:cytology / Q000378:metabolism / Q000821:virology*; D006377:T-Lymphocytes, Helper-Inducer / Q000166:cytology* / Q000187:drug effects / Q000821:virology; D054311:nef Gene Products, Human Immunodeficiency Virus; D054322:tat Gene Products, Human Immunodeficiency Virus
D015704:CD4 Antigens; D002630:Chemotactic Factors; D017077:Culture Media, Conditioned; D015693:Gene Products, nef; D015696:Gene Products, tat; D054311:nef Gene Products, Human Immunodeficiency Virus; D054322:tat Gene Products, Human Immunodeficiency Virus